World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
97
Citations
33322
World Ranking
9315
National Ranking
4805

Christopher H. Crane publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Christopher H. Crane sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 534 publications — 63rd percentile

63% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Christopher H. Crane D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Christopher H. Crane sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 97 D-Index — 55th percentile

55% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Christopher H. Crane is primarily affiliated with Memorial Sloan Kettering Cancer Center in the United States. Their research contributions span extensively across the field of medicine, with a significant focus on oncology. The subfields within their work include oncology, surgery, pulmonary and respiratory medicine, radiology, nuclear medicine and imaging, and radiation.

Their recent publication record demonstrates active engagement in clinical and translational cancer research. Notable recent papers include:

  • PD-1 Blockade in Mismatch Repair-Deficient, Locally Advanced Rectal Cancer, 2022, New England Journal of Medicine
  • Metastatic Pancreatic Cancer: ASCO Guideline Update, 2020, Journal of Clinical Oncology
  • Association of Ablative Radiation Therapy With Survival Among Patients With Inoperable Pancreatic Cancer, 2021, JAMA Oncology
  • Conventionally fractionated radiation therapy versus stereotactic body radiation therapy for locally advanced pancreatic cancer (CRiSP): An international systematic review and meta-analysis, 2020, Cancer
  • Phase II Single-arm Study of Durvalumab and Tremelimumab with Concurrent Radiotherapy in Patients with Mismatch Repair-proficient Metastatic Colorectal Cancer, 2021, Clinical Cancer Research

Frequent co-authors collaborating with Christopher H. Crane include:

  • Paul B. Romesser
  • Marsha Reyngold
  • Carla Hajj
  • Abraham J. Wu
  • Martin R. Weiser

Their work has been published primarily in a range of journals, with the most frequent venues being:

  • Cancer
  • International Journal of Radiation Oncology*Biology*Physics
  • Journal of Clinical Oncology
  • Cancers
  • Advances in Radiation Oncology

The main research topics that characterize Christopher H. Crane's scientific contributions cover:

  • Colorectal and Anal Carcinomas
  • Pancreatic and Hepatic Oncology Research
  • Advanced Radiotherapy Techniques
  • Colorectal Cancer Surgical Treatments
  • Hepatocellular Carcinoma Treatment and Prognosis
  • Cancer Genomics and Diagnostics
  • Gastric Cancer Management and Outcomes

Their research profile reflects a focus on both clinical treatment strategies and cancer biology, especially pertaining to colorectal, pancreatic, hepatic, and gastric malignancies. The frequent engagement with advanced radiotherapy techniques also indicates a specialization in improving therapeutic approaches within oncology.

Best Publications

  • Borderline Resectable Pancreatic Cancer: Definitions, Management, and Role of Preoperative Therapy

    Gauri R. Varadhachary;Eric P. Tamm;James L. Abbruzzese;Henry Q. Xiong

  • Gemcitabine Alone Versus Gemcitabine Plus Radiotherapy in Patients With Locally Advanced Pancreatic Cancer: An Eastern Cooperative Oncology Group Trial

    Patrick J. Loehrer;Yang Feng;Higinia Cardenes;Lynne Wagner

  • Borderline resectable pancreatic cancer: the importance of this emerging stage of disease.

    Matthew H.G. Katz;Peter W.T. Pisters;Douglas B. Evans;Charlotte C. Sun

  • Preoperative Gemcitabine-Based Chemoradiation for Patients With Resectable Adenocarcinoma of the Pancreatic Head

    Douglas B. Evans;Gauri R. Varadhachary;Christopher H. Crane;Charlotte C. Sun

  • Impact of resection status on pattern of failure and survival after pancreaticoduodenectomy for pancreatic adenocarcinoma

    Chandrajit P. Raut;Jennifer F. Tseng;Jennifer F. Tseng;Charlotte C. Sun;Huamin Wang

  • Pancreaticoduodenectomy with vascular resection: margin status and survival duration

    Jennifer F. Tseng;Chandrajit P. Raut;Jeffrey E. Lee;Peter W.T. Pisters

  • Long-Term Survival After Multidisciplinary Management of Resected Pancreatic Adenocarcinoma

    Matthew Harold Katz;Matthew Harold Katz;Huamin Wang;Jason B Fleming;Charlotte C Sun

  • Response of borderline resectable pancreatic cancer to neoadjuvant therapy is not reflected by radiographic indicators

    Matthew Harold Katz;Jason B Fleming;Priya R Bhosale;Gauri R Varadhachary

  • Phase II Trial of Preoperative Chemoradiation in Patients With Localized Gastric Adenocarcinoma (RTOG 9904): Quality of Combined Modality Therapy and Pathologic Response

    Jaffer A. Ajani;Kathryn Winter;Gordon S. Okawara;John H. Donohue

  • Preoperative Gemcitabine and Cisplatin Followed by Gemcitabine-Based Chemoradiation for Resectable Adenocarcinoma of the Pancreatic Head

    Gauri R. Varadhachary;Robert A. Wolff;Christopher H. Crane;Charlotte C. Sun

  • Adoption of Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer.

    Andrea Cercek;Campbell S.D. Roxburgh;Campbell S.D. Roxburgh;Paul Strombom;J. Joshua Smith

  • Neoadjuvant Treatment Response As an Early Response Indicator for Patients With Rectal Cancer

    In Ja Park;Y. Nancy You;Atin Agarwal;John M. Skibber

  • Multi-Institutional Phase II Study of High-Dose Hypofractionated Proton Beam Therapy in Patients With Localized, Unresectable Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma.

    Theodore S. Hong;Jennifer Y. Wo;Beow Y. Yeap;Edgar Ben-Josef

  • Neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreas: treatment variables and survival duration.

    T. M. Breslin;K. R. Hess;D. B. Harbison;M. E. Jean

  • Assessment of a Watch-and-Wait Strategy for Rectal Cancer in Patients With a Complete Response After Neoadjuvant Therapy

    J. Joshua Smith;Paul Strombom;Oliver S. Chow;Campbell S. Roxburgh;Campbell S. Roxburgh

  • Mutation Profiling in Cholangiocarcinoma: Prognostic and Therapeutic Implications

    Chaitanya R. Churi;Rachna Shroff;Ying Wang;Asif Rashid

  • Predictors of tumor response and downstaging in patients who receive preoperative chemoradiation for rectal cancer.

    Prajnan Das;John M. Skibber;Miguel A. Rodriguez-Bigas;Barry W. Feig

  • Hilar Cholangiocarcinoma: expert consensus statement

    John C. Mansour;Thomas A. Aloia;Christopher H. Crane;Julie K. Heimbach

  • Adjuvant Therapy for Resected Biliary Tract Cancer: ASCO Clinical Practice Guideline.

    Rachna T. Shroff;Erin B. Kennedy;Melinda Bachini;Tanios Bekaii-Saab

  • Phase II Trial of Cetuximab, Gemcitabine, and Oxaliplatin Followed by Chemoradiation With Cetuximab for Locally Advanced (T4) Pancreatic Adenocarcinoma: Correlation of Smad4(Dpc4) Immunostaining With Pattern of Disease Progression

    Christopher H. Crane;Gauri R. Varadhachary;John S. Yordy;Gregg A. Staerkel

Frequent Co-Authors

Robert A. Wolff
Robert A. Wolff The University of Texas MD Anderson Cancer Center
Sunil Krishnan
Sunil Krishnan The University of Texas MD Anderson Cancer Center
John M. Skibber
John M. Skibber The University of Texas MD Anderson Cancer Center
Douglas B. Evans
Douglas B. Evans Medical College of Wisconsin
Cathy Eng
Cathy Eng Vanderbilt University
Miguel A. Rodriguez-Bigas
Miguel A. Rodriguez-Bigas The University of Texas MD Anderson Cancer Center
Barry W. Feig
Barry W. Feig The University of Texas MD Anderson Cancer Center
James L. Abbruzzese
James L. Abbruzzese Duke University
Jason B. Fleming
Jason B. Fleming The University of Texas MD Anderson Cancer Center
George J. Chang
George J. Chang The University of Texas MD Anderson Cancer Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring Medicine in the USA opens doors to diverse healthcare career paths that extend well beyond the traditional MD. Many students consider practical alternatives such as lpn program options, which offer fast-track entry into nursing and patient care through online learning. For those already holding advanced degrees, the fastest post master's pmhnp programs provide an accelerated route to specialize in psychiatric-mental health as a nurse practitioner.

If you’re interested in healthcare leadership or operations, consider earning a bachelors in healthcare administration for foundational skills in managing healthcare organizations. Those looking to advance further in this field may benefit from cheapest mha programs online, which deliver essential business and managerial training at an affordable cost.

Whether your interests lie in clinical, mental health, or administrative roles, these pathways offer flexible online options for advancing your career in healthcare.

Best Scientists Citing Christopher H. Crane

Trending Scientists

Recently Published Articles